Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Ethylmaleimide (NEM) is a small molecule derived from maleic acid and classified as a maleimide. It is a highly reactive Michael acceptor that selectively alkylates thiol (sulfhydryl) groups in proteins and peptides—most notably cysteine residues—forming stable thioether bonds. This reaction is virtually irreversible under physiological conditions. NEM acts as an irreversible inhibitor of all cysteine peptidases by covalently modifying the active site thiol group. It has been widely used in biochemical research to probe the functional role of protein thiols and to inhibit enzymes such as deubiquitinases and certain kinases. In addition to its use in protein modification studies (e.g., blocking de-sumoylation or DNA fragmentation), it serves roles in bioconjugation chemistry for attaching biomolecules to surfaces or other molecules and has applications in polymer synthesis and diagnostics[1][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-ethylmaleimide.